Illumina, Inc. (ILMN)
After hours:
| Previous close | 208.70 |
| Open | 209.10 |
| Bid | 212.00 x 1100 |
| Ask | 215.91 x 800 |
| Day's range | 206.02 - 217.48 |
| 52-week range | 173.45 - 371.16 |
| Volume | |
| Avg. volume | 1,183,608 |
| Market cap | 33.936B |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | 48.59 |
| EPS (TTM) | 4.44 |
| Earnings date | 07 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 243.50 |
- Financial Times
Illumina boosts spending on US lobbying amid opposition to Grail acquisition
Illumina sharply increased its spending on lobbying over the past two years as it tried to build support against antitrust regulators in the US and Europe that have attempted to block its $8bn acquisition of cancer testing company Grail. The world’s biggest genome sequencing company and its subsidiary Grail spent a combined $14.6mn in 2021 and 2022 on federal lobbying in the US, more than five times the $2.72mn combined they spent in the previous two years, according to public disclosures. Illumina was the fourth-largest spender on lobbying among biotech and pharma companies in 2022 at $9.4mn, behind only Pfizer, Roche and Amgen, which are much larger companies, according to an analysis by OpenSecrets, a transparency group.
- Zacks
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
